Can Journavx (suzetrigine) be used for cancer pain in adults who have exhausted standard therapies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Journavx (Suzetrigine) Should NOT Be Used for Cancer Pain

Journavx is FDA-approved exclusively for moderate to severe acute pain in adults and is not indicated for cancer pain management. 1 The drug label explicitly limits its use to acute pain conditions, and current cancer pain guidelines do not include suzetrigine in their treatment algorithms.

Why This Recommendation is Clear

FDA Indication is Restrictive

The FDA approval for Journavx (suzetrigine) is specifically and only for moderate to severe acute pain in adults 1. This indication was based on two 48-hour postoperative pain trials (abdominoplasty and bunionectomy), not cancer-related pain conditions 1. The drug has no established role, safety data, or efficacy evidence in the chronic, complex pain syndromes characteristic of cancer.

Cancer Pain Guidelines Do Not Include Suzetrigine

The most recent NCCN Adult Cancer Pain Guidelines (2025) 2 and ESMO Clinical Practice Guidelines (2018) 3 provide comprehensive treatment algorithms for cancer pain management. Neither guideline mentions suzetrigine or selective NaV1.8 inhibitors as treatment options. The established framework remains:

  • First-line: Acetaminophen, NSAIDs for mild pain
  • Second-line: Weak opioids (codeine) for moderate pain
  • Third-line: Strong opioids (morphine, oxycodone, fentanyl) for moderate to severe pain
  • Adjuvants: Anticonvulsants, antidepressants, corticosteroids for neuropathic components
  • Interventional: Nerve blocks, neuraxial analgesia, neurosurgical procedures for refractory cases

2, 3

Limited and Negative Clinical Experience

A 2026 case series specifically evaluated suzetrigine in three patients with metastatic cancer-related bone pain who had failed conventional therapies 4. All three patients showed no meaningful improvement after three weeks of treatment, and therapy was discontinued due to lack of efficacy. While this is limited data, it represents the only published experience with suzetrigine in cancer pain and suggests the drug may be ineffective in this population, particularly in opioid-tolerant patients with advanced disease.

Critical Distinctions Between Acute and Cancer Pain

Mechanism Mismatch

Suzetrigine works by selectively inhibiting NaV1.8 sodium channels in peripheral nociceptors 5, 6. While this mechanism shows efficacy in acute nociceptive pain from tissue injury, cancer pain involves:

  • Mixed pathophysiology: Nociceptive (somatic and visceral), neuropathic, and nociplastic components 2, 3
  • Chronic sensitization: Central and peripheral nervous system changes that may not respond to peripheral NaV1.8 blockade alone
  • Tumor-specific mechanisms: Inflammatory mediators, bone destruction, nerve infiltration, and visceral distension that create complex pain states

Duration Limitations

The FDA approval and clinical trial data support only short-term use (48 hours) 1. Cancer pain typically requires:

  • Continuous management: Weeks to months of treatment
  • Dose titration: Gradual escalation based on response
  • Long-term safety data: Which does not exist for suzetrigine beyond acute postoperative settings

When Opioids Have Failed

Even in patients who have "exhausted standard therapies," suzetrigine is not the appropriate next step. The evidence-based approach includes:

  1. Reassess the pain syndrome: Ensure accurate characterization of nociceptive vs. neuropathic components 2, 3
  2. Optimize opioid therapy: Consider opioid rotation, route changes (transdermal, subcutaneous, neuraxial), or methadone for complex pain 2
  3. Maximize adjuvant therapy: Gabapentinoids for neuropathic pain, corticosteroids for inflammatory/bone pain, antidepressants for mixed syndromes 3
  4. Interventional procedures: Nerve blocks, epidural/intrathecal analgesia, neurolytic procedures, vertebroplasty for bone metastases 2
  5. Palliative care consultation: Early referral improves pain control and quality of life 2, 3

Important Caveats

Drug Interactions

Suzetrigine induces CYP3A and to a lesser extent CYP2B6, CYP2C8, CYP2C9, and CYP2C19 1. Many cancer patients are on:

  • Chemotherapy agents: Often CYP3A substrates
  • Antiemetics: Potential for reduced efficacy
  • Hormonal therapies: May be affected by enzyme induction

This creates additional risk without proven benefit.

Cost Considerations

The case series noted cost as a barrier to continued treatment 4. For an unproven indication, this represents poor resource allocation when evidence-based alternatives exist.

Off-Label Use Risks

Using suzetrigine off-label for cancer pain means:

  • No dosing guidance for chronic use
  • Unknown safety profile beyond 48 hours
  • No efficacy data in the target population
  • Potential insurance denial and patient financial burden

The Bottom Line

Do not use Journavx for cancer pain. The drug is approved only for acute pain, has no supporting evidence in cancer populations, showed no benefit in the limited published experience with cancer-related bone pain, and is not included in any cancer pain management guidelines. Stick to the established WHO analgesic ladder and evidence-based multimodal approaches, with early palliative care involvement for complex cases 2, 3.

References

2
Guideline

adult cancer pain, version 2.2025, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Related Questions

What is the efficacy of suzetrigine (Journavx) and what is the recommended prescribing regimen for short‑term treatment of moderate‑to‑severe acute postoperative pain in adults?
What is the newly approved oral sodium‑channel blocker indicated for acute postoperative pain management?
In a patient maintained on Suboxone (buprenorphine/naloxone) who has a fracture with worsening pain, can JOURNAVX (suzetrigine) be used for analgesia?
How should I start and manage Journavx (suvetrigine) therapy, including dose, timing relative to meals, drug interactions, side effects, and alternative pain options?
Is it safe to use JOURNAVX (suzetrigine) with topical lidocaine for radiofrequency microneedling?
What are the clinical manifestations of adrenal insufficiency and which laboratory tests should be ordered to evaluate it?
What is the recommended management for a 21‑week pregnant patient whose gallbladder is almost completely distended with stones?
What is the acute management of a cyanotic spell in a child with Tetralogy of Fallot?
What is the relationship between osteoporosis and arthritis?
Can oseltamivir (Tamiflu) cause headaches after completing treatment?
When should a patient take glipizide and Jardiance (empagliflozin) relative to meals—before, with, or without food?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.